Alexion Pharmaceuticals – Company Information

Alexion Pharmaceuticals, Inc. is a multinational biopharmaceutical company based in Cheshire, Connecticut, USA.

The company is well known for being the¬†the first¬†developer and distributor of its sole marketed¬†drug ‘Soliris’, which is¬†the world’s first and only approved terminal complement inhibitor – used¬†for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Its flagship drug Soliris is currently approved in more than 50 countries as a treatment option for PNH. It is also approved as treatment for patients with atypical hemolytic uremic syndrome (aHUS) in the US, EU, and Japan.

Alexion was formed¬†in 1992 and became a public company in 1996 on the NASDAQ stock exchange under the ticker symbol ‘ALXN’. It is now¬†a multi-national company with more than 2,200 dedicated employees worldwide.

According to Alexion, the company is “focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases.”

Overview

Alexion Pharmaceuticals logo

  • Chairman and CEO:¬†Leonard Bell
  • Industry: Pharmaceutical
  • Type:¬†Public company
  • Listed on¬†NASDAQ
  • NASDAQ¬†stock symbol:¬†ALXN
  • S&P 500 Component
  • Founded:¬†1992
  • Sales:¬†$2.233 billion USD (2014)
  • Net income: $656.912 million USD (2014)
  • Earnings per share: $3.32 USD (2014)
  • Company head office:¬†352 Knotter Drive Cheshire, CT 06410, USA
  • Employees: 2,273 (2014)
  • Website:¬†http://www.alxn.com/
  • Global headquarters contact number:¬†203-272-ALXN (2596)

Alexion Pharmaceuticals, Inc., Financial Results, Years Ended December 31

Operating data (in $ thousands) 2014 2013
Net product sales $2,233,733 $1,551,346
Total cost of sales $173,862 $177,556
Research and development expenses $513,782 $317,093
Selling, general, and administrative expenses $630,209 $489,720
Acquisition-related costs $20,295 $5,029
Total operating expenses $1,191,165 $845,780
Operating income $868,706 $528,010
Income before income taxes $872,107 $526,269
Net income $656,912 $252,895
Balance sheet data (in $ thousands)
Total assets $4,201,962 $3,317,696
Total liabilities $899,944 $935,617
Total stockholders’ equity $3,302,018 $2,382,079
Common share data (in $)
Basic earnings per share $3.32 $1.29
Diluted earnings per share $3.26 $1.27

Source: “Alexion Pharmaceuticals, Inc., Form 10-K 2014”¬†